Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29715
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrenkel, J-
dc.contributor.authorAnton, J-
dc.contributor.authorLivneh, A-
dc.contributor.authorVAN DER HILST, Jeroen-
dc.date.accessioned2019-10-09T13:35:28Z-
dc.date.available2019-10-09T13:35:28Z-
dc.date.issued2016-
dc.identifier.citationArthritis & Rheumatology, 68(10) (Art N° 2378)-
dc.identifier.issn2326-5191-
dc.identifier.urihttp://hdl.handle.net/1942/29715-
dc.language.isoen-
dc.titlePharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial-
dc.typeJournal Contribution-
dc.identifier.issue10-
dc.identifier.volume68-
local.bibliographicCitation.jcatM-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnr2378-
local.classIncludeIn-ExcludeFrom-List/ExcludeFromFRIS-
dc.identifier.isi000417143404008-
dc.identifier.urlhttps://acrabstracts.org/abstract/pharmacokinetic-and-pharmacodynamic-characteristics-of-canakinumab-in-patients-with-periodic-fever-syndromes-results-from-a-phase-iii-pivotal-umbrella-trial/-
item.fulltextNo Fulltext-
item.contributorFrenkel, J-
item.contributorAnton, J-
item.contributorLivneh, A-
item.contributorVAN DER HILST, Jeroen-
item.accessRightsClosed Access-
item.fullcitationFrenkel, J; Anton, J; Livneh, A & VAN DER HILST, Jeroen (2016) Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial. In: Arthritis & Rheumatology, 68(10) (Art N° 2378).-
crisitem.journal.issn2326-5191-
crisitem.journal.eissn2326-5205-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Oct 7, 2024

Page view(s)

12
checked on Jul 28, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.